NCT00222053View on ClinicalTrials.gov

IFM 99-02 Thalidomide in Myeloma

PHASE3CompletedINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

April 30, 2000

Primary Completion Date

September 30, 2009

Study Completion Date

December 31, 2009

Conditions
Multiple Myeloma
Interventions
DRUG

Thalidomide

Per os thalidomide

DRUG

Biphosphonates

Biphosphonates

Trial Locations (5)

Unknown

Médecine Interne, CHU Purpan, Toulouse

Médecine Interne, Hôpital Rangueil, Toulouse

Rhumatologie, CHU Purpan, Toulouse

Rhumatologie, CHU Rangueil, Toulouse

Service d'hématologie, CHU Purpan, Toulouse

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER

NCT00222053 - IFM 99-02 Thalidomide in Myeloma | Biotech Hunter | Biotech Hunter